Search Results
Site Search
Managing Operational Surprises in Real Time - Insights
While preparation is key to mitigating risk, inevitably, there are unforeseen circumstances that will impact operations. Here are four ways the outreach laboratory can swiftly manage operational surprises in real time.
Assay identifies rare tick-borne bacteria: Bobbi Pritt, M.D. - Insights
Bobbi Pritt, M.D., explains how Mayo Clinic Laboratories' new assay identifies less-common tick-borne bacteria in whole blood. The assay is recommended when tick-borne bacterial infection is suspected but standard testing is unrevealing.
Memorial Day 2024 Specimen Shipping Guidelines and Schedule - Insights
Mayo Clinic Laboratories specimen pickup and delivery schedules will be altered due to the upcoming Memorial Day holiday on Monday, May 27, 2024. To ensure specimen stability and prevent delays, follow the guidelines below outlined for...
Labor Day Specimen Shipping Guidelines and Schedule - Insights
Mayo Clinic Laboratories specimen pickup and delivery schedules will be altered due to the upcoming holiday. To ensure specimen stability and prevent delays, follow these guidelines.
Chain of Custody Testing - Insights
Loralie Langman, Ph.D., explains the difference between chain of custody and clinical toxicology testing. Chain of custody is a process used for toxicology testing when the results might have legal implications for the individual tested....
The following on demand education is related to the “Other” category in medical laboratory science (MLS), which encompasses a variety of specialized topics and emerging areas that don’t fall into traditional categories like hematology,...
Antibody against the GABA-A receptor is a biomarker of autoimmune encephalopathy that occurs across the lifespan, and disproportionately affects children. In this test-specific episode of the "Answers From the Lab" podcast, Andrew McKeon,...
Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing...
Alzheimer's Disease 2024: The Role of Biomarkers - Insights
PACE/State of FL - The latest updates in Alzheimer’s disease diagnostic criteria as well as a comprehensive review of the laboratory testing landscape.
Mayo Clinic Laboratories and Progentec launch lupus advanced biomarker testing services - Insights
As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating...
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels,...
Urologic panels provide focused cancer testing: Sounak Gupta, M.B.B.S., Ph.D. - Insights
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS...
Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for...
Multiple Sclerosis Profile Updates - Insights
Maria Alice Willrich, Ph.D., explains kappa free light chain testing — Mayo Clinic Laboratories' data-driven approach to diagnose multiple sclerosis. The automated assay is more sensitive, cost-effective, and faster than traditional...
An efficient, cost-effective, fungal testing alternative: Elitza Theel, Ph.D. - Insights
Elitza Theel, Ph.D., explains how Mayo Clinic Laboratories' unique Histoplasma/Blastomyces test provides cost-effective evaluation for fungal infections that cause pulmonary illness. The assay reliably detects both Histoplasma and...
Hereditary Oncology Testing [Test in Focus] - Insights
Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant...
Disaccharidase Activity Panel [Test in Focus] - Insights
Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead to chronic conditions like celiac...
Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild...
The importance of blood inventory and diversity in supply - Insights
Maintaining a diverse and sufficient blood supply is essential for hospital care, as transfusions support many critical treatments. Several known red blood cell antigens make donor-recipient matching complex, especially across diverse...
Thrombotic Microangiopathies (TMA) [Test in Focus] - Insights
Meera Sridharan, M.D., Ph.D., explains Mayo Clinic Labs’ testing approach for atypical hemolytic uremic syndrome (aHUS). The serological complement panel examines nine analytes to gain a thorough understanding of the complement cascade to...
State-of-the-art genetics panel optimizes kidney disease treatment - Insights
Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive, accurate and actionable results. Identifying a genetic cause helps guide the complex decisions...
Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. - Insights
Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal...
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay...
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted...
Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related...
Linnea Baudhuin, Ph.D., and Kate Kotzer, M.S., CGC, describe how Mayo Clinic Laboratories' postmortem genetic tests can provide answers after a sudden unexplained cardiac death. Test results are important for managing family members' risk...
Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for...
Memorial Day Specimen Shipping Alert - Insights
Due to the Memorial Day holiday (recognized on Monday, May 26), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure that your specimen vitality and turnaround times are not affected, please note the...
Monitoring Hurricane Milton - Insights
Hurricane Milton is approaching the west coast of Florida and is anticipated to make landfall Wednesday. We continue to monitor and track the situation with our logistics partners to minimize challenges.
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in...
Updates Streamline Autoimmune Neurology Testing: Anastasia Zekeridou, M.D., Ph.D. - Insights
Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating...
Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of...
Tests aid diagnosis of primary biliary cholangitis: Anne Tebo, Ph.D. - Insights
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune...
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test...
Assay enhances and simplifies M-proteins screening: David Murray, M.D., Ph.D. - Insights
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASSFIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the...
Mayo Clinic Laboratories easily consumable content, ensuring knowledge retention in minimal time. These microlearning educational offerings will cover a variety of topics relevant to current and aspiring laboratory leaders.
Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D. - Insights
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely...
Mayo Clinic Laboratories and KYAN Technologies announced a collaboration to validate and provide the KYAN test, Optim.AI™, across the United States.
Practical Approaches to Outreach Marketing - Insights
Marketing is an essential discipline of any successful laboratory outreach program. While specific marketing goals and audiences will differ for every program, most of them will certainly involve driving awareness and growth. A strong...
Outreach Quality and Satisfaction - The Patient's View - Insights
As healthcare continues to evolve and payment models become more inclusive of patient satisfaction measures, it is vitally important for laboratories to focus on improving the patient experience. Because the laboratory is a critical element...
Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC - Insights
Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many...
Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to...
Cytology Specimen Utilization: A Proven Approach to Genetic Sequencing - Insights
PACE/State of FL - The role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer.
Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D. - Insights
John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
Communiqué Archives - Page 3 of 4 - Insights
Skip to Content MayoACCESS MayoLINK Register My Dashboard...
There have been concerns in the U.S. recently about the possible harmful side effects from absorbing gadolinium-based contrast agents into the body during some MRI exams. To address some of the anxiety and concerns over this issue, Paul...
Cutting-edge lab work cracks a medical mystery: Kenneth Hobby - Insights
Kenneth Hobby assumed his fever, fatigue, and aching pains in May 2018 were from another bout of malaria. He was on one of his frequent visits to Zambia in southern Africa, where the mosquito-borne parasite is common. But anti-malaria drugs...
Myasthenia Gravis [Test in Focus] - Insights
Christopher Klein, M.D., discusses Mayo Clinic’s updated myasthenia gravis and Lambert-Eaton syndrome testing approach. Automatic reflex to second-line testing saves time and increases sensitivity and specificity to confirm diagnosis in...